Clinical Trials
2 trialsNCT05470491 2026-06-03
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT01785810 2021-01-11
Phase II Maraviroc for GVHD Prevention
Abramson Cancer Center at Penn Medicine
Phase 2 Completed